Eisai Dips Toe Into Chinese Generics With TianYi Buy
This article was originally published in PharmAsia News
Executive Summary
Major Japanese innovator Eisai is moving into the Chinese generics sector through the acquisition of the small Chinese firm Liaoning TianYi Biological, in a move it says is designed to tap into strong projected market growth for such products in China.
You may also be interested in...
China Options For Takeda As It Pursues Emerging Markets Buy
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.